研究人员发现并分析了CAR-T治疗的罕见但严重的副作用。

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy.

莱比锡大学医院、弗劳恩霍夫细胞治疗和免疫学研究所以及科隆大学医院的科学家发表了这项研究的结果。

The results of the study have been published by scientists from Leipzig University Hospital, the Fraunhofer Institute for Cell Therapy and Immunology and Cologne University Hospital.

淋巴瘤和多发性骨髓瘤都是源自免疫细胞淋巴细胞的恶性肿瘤疾病。

Forms of blood cancer, such as lymphomas and multiple myeloma, are malignant tumor diseases that are derived from immune cells, the lymphocytes.

几年来，CAR - T细胞疗法已经成为淋巴瘤或多发性骨髓瘤复发患者治疗的重要组成部分。

For a few years now, CAR T-cell therapies have been an essential part of the treatment of patients whose lymphoma or multiple myeloma recurs.

一名63岁的多发性骨髓瘤患者在科隆大学医院接受CAR - t细胞治疗9个月后患上了T细胞淋巴瘤，这种淋巴瘤不仅出现在血液中，而且出现在皮肤和肠道中。

A 63-year-old patient with multiple myeloma developed a T-cell lymphoma nine months after undergoing CAR T-cell therapy at the University Hospital of Cologne, which appeared not only in the blood but also in the skin and intestines.

肿瘤是由用于治疗的CART细胞发展而来的。

The tumor developed from the genetically modified T-cells that had been used for treatment.

这是CAR - t细胞治疗后首次记录的此类淋巴瘤病例之一。

This is one of the first documented cases of such lymphoma after CAR T-cell therapy.

研究人员发现，不仅仅是T细胞当前的基因变化导致了肿瘤。

The researchers found that it was not only current genetic changes in the T cells that were responsible for the tumor.

预先存在的，即患者造血细胞的早期遗传变化也起了作用。

Pre-existing, i.e. early genetic changes in the patient's hematopoietic cells also played a role.

临床医生和CAR-T细胞治疗领域的基础科学家之间的密切合作使得在很短的时间内分析病例成为可能。

The close cooperation between clinicians and basic scientists in the field of CAR-T cell therapy made it possible to analyze the case within a very short time.

研究人员正在计划进一步的科学研究，以更好地了解类似的病例，并能够更准确地确定风险因素。

The researchers are planning further scientific studies to better understand similar cases and to be able to determine risk factors more precisely.

其目的是在未来能够预测和预防CAR-T细胞治疗后的副作用，目前CAR-T细胞治疗的应用越来越广泛。

The aim is to be able to predict and prevent such side effects after CAR-T cell therapies, which are currently being used more and more widely, in the future.

该研究小组于2月中旬向《白血病》（Leukemia）投稿，系统地总结了该患者病例和世界上发表的其他9例CAR-T细胞t细胞淋巴瘤病例。

The same research team submitted a manuscript to the high-ranking journal Leukemia in mid-February, systematically summarizing this patient case and the nine other cases of T-cell lymphomas from CAR-T cells published worldwide.

Cite this article

Braun, T., Rade, M., Merz, M. et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat Med (2025). https://doi.org/10.1038/s41591-025-03499-9